Precision Medicine Is Precisely Right Theme For Biopharma: Impact Of Therapy—Not Cost—Is Focus
This article was originally published in RPM Report
Executive Summary
A Senate hearing on President Obama’s Precision Medicine initiative illustrates how well that theme plays for the biopharma sector. The focus was on the potential for highly effective targeted therapies to help patients—and even lower costs for the system. The price of the drugs themselves was not even raised.
You may also be interested in...
Sen. Warren’s “War on Pharma”: Rhetorical Blast, But Remarkably Limited Objectives
Despite her reputation as a populist, anti-corporate crusader, Elizabeth Warren did not focus on Big Pharma in her first years in the Senate. The headlines following a speech by Warren last week suggest that has changed – but the actual legislative proposal looks a lot different than the rhetoric makes it sound.
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.